Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the extent of liver fibrosis yet there is little evidence quantifying the cost effectiveness of RGT particularly conditional upon fibrosis stage.
This study describes an economic model designed to assess the costs and benefits of RGT compared with standard duration of therapy (SDT) in hepatitis C virus genotype 1 patients.
A Markov cohort simulation model with lifetime perspective was developed to undertake a cost utility analysis of RGT in the UK. Patients entered the model at Metavir disease stages F0–F4, and progressed through these stages via age and duration of HCV infection-dependent transition probabilities. Treated patients were partitioned according to virological response and shortened or extended duration of therapy was applied following European guidelines.
For all patients, SDT and RGT was associated with an increase of 2.14 and 2.20 QALYs and £2,374 and £2,270 costs, respectively, compared with no treatment. Overall, RGT was a dominant scenario being associated with a lower risk of complications, increased QALYs (0.08) and cost saving (£101). RGT across fibrosis stages was either highly cost effective or dominant; in all cases RGT was associated with an increase in QALYs, driven by a reduction in complications in DVR subjects and reduced exposure to treatment disutility in RVR subjects; costs were lower in F1 and F2 fibrosis stages. At a willingness-to-pay threshold of £20,000 per QALY, overall RGT across fibrosis stages F2–F4 were associated with the highest probability of being cost effective. At this threshold, the probability of reduced/extended therapy in RVR/DVR patients being cost effective is 0.35 and 0.88, respectively.
This analysis suggests that the treatment of HCV genotype 1 patients in fibrosis stage F2 has the greatest potential for maximizing health benefit and cost saving within an RGT protocol. Predicting those patients most likely to respond to treatments is important from both a clinical and cost perspective and the tailoring of treatment duration with the current standard of care is likely to remain a priority for payers with budgetary constraints.
- Lavanchy, D (2009) The global burden of hepatitis C. Liver Int 29: pp. 74-81 CrossRef
- Shepard, CW, Finelli, L, Alter, MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: pp. 558-567 CrossRef
- Seeff, LB (2002) Natural history of chronic hepatitis C. Hepatology 36: pp. S35-S46 CrossRef
- Thompson Coon, J, Rogers, G, Hewson, P, Wright, D, Anderson, R, Jackson, S (2008) Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 98: pp. 1166-1175 CrossRef
- Calvaruso, V, Craxì, A (2012) 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 32: pp. 2-8 CrossRef
- Harris, RJ, Ramsay, M, Hope, VD, Brant, L, Hickman, M, Foster, GR (2012) Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 22: pp. 187-192 CrossRef
- Hepatitis C in the UK: 2011 Report. Health Protection Agency, London
- Schlütter, J (2011) Therapeutics: new drugs hit the target. Nature 474: pp. S5-S7 CrossRef
- Sroczynski, G, Esteban, E, Conrads-Frank, A, Schwarzer, R, Mühlberger, N, Wright, D (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 17: pp. 34-50 CrossRef
- Nakamura, J, Kobayashi, K, Toyabe, SI, Aoyagi, Y, Akazawa, K (2007) The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol 19: pp. 733-739 CrossRef
- Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):i–xii, 1–210.
- Nakamura, J, Toyabe, SI, Aoyagi, Y, Akazawa, K (2008) Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat 15: pp. 293-299 CrossRef
- Thein, HH, Yi, Q, Dore, GJ, Krahn, MD (2008) Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48: pp. 418-431 CrossRef
- Sullivan, SD, Craxi, A, Alberti, A, Giuliani, G, Carli, C, Wintfeld, N (2004) Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 22: pp. 257-265 CrossRef
- Sullivan, SD, Jensen, DM, Bernstein, DE, Hassanein, TI, Foster, GR, Lee, SS (2004) Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 99: pp. 1490-1496 CrossRef
- Mangia, A, Andriulli, A (2010) Tailoring the length of antiviral treatment for hepatitis C. Gut 59: pp. 1-5 CrossRef
- Pearlman, BL (2008) Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J Gastroenterol 14: pp. 3621-3627 CrossRef
- Cheng, WSC, Roberts, SK, McCaughan, G, Sievert, W, Weltman, M, Crawford, D (2010) Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 53: pp. 616-623 CrossRef
- British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London
- Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8(39):iii–iv, 1–125.
- Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007;11(11):1–205, iii.
- Martin, NK, Vickerman, P, Miners, A, Foster, GR, Hutchinson, SJ, Goldberg, DJ (2012) Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55: pp. 49-57 CrossRef
- Clark, PJ, Thompson, AJ, McHutchison, JG (2011) IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 106: pp. 38-45 CrossRef
- Alberti, A (2011) Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 31: pp. 18-22 CrossRef
- Ciesek, S, Manns, MP (2011) Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 8: pp. 69-71 CrossRef
- Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model
Applied Health Economics and Health Policy
Volume 11, Issue 1 , pp 53-63
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Centre for Health Economics, Swansea University, Swansea, Wales, UK
- 4. Swansea Centre for Health Economics, Westgate House, Womanby Street, Cardiff, CF10 1BR, UK
- 2. Mayo Clinic College of Medicine, Rochester, MN, USA
- 3. Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA